User menu

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

Bibliographic reference Giles, Francis ; Verstovsek, Srdan ; Faderl, Stefan ; Vey, Norbert ; Karp, Judy ; et. al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.. In: Leukemia research, Vol. 30, no. 12, p. 1591-5 (2006)
Permanent URL http://hdl.handle.net/2078.1/26945